DUBLIN, May 11, 2015 /PRNewswire/ --
British Ambassador to Ireland, Dominick Chilcott opened discussions on the EU Falsified Medicines Directive (FMD), enabled by Aegate, the medicine verification leading experts.
Representatives included manufacturers, wholesalers, pharmacists, patient groups, PMR pharmacy software houses and regulatory bodies who are keen to benefit from a real time, end to end authentication service ensuring patient safety at point of dispense. Aegate demonstrated expertise in performance, reliability and security through 7 years' operational experience throughout Europe in medicines authentication.
Aegate raised important questions around the practical issues and complications of implementing the FMD including hospital coverage, how wholesalers will operate with parallel traders and how the national groups will govern the regulation and ensure continuity.
Stakeholders recognise the value of Aegate sharing this information and their value proposition to stakeholders. Participants were pleased that Aegate called this discussion.
There is agreement that the process for appointing a service provider should be accelerated, and a decision made at the earliest opportunity to meet the local needs in Ireland.
Graham Smith, Aegate Commercial Director commented, "We had a great evening at the Ambassador's residence sharing Aegate's practical authentication experience with local stakeholders."
With a documented history of some 3 billion medicines scanned to date with an average rate of 200,000 transactions per hour across 17,000 dispensing points, Aegate is the principal active market leader in medicines verification. Aegate's Reach, Assure and Protect services meet the needs of all stakeholders. Supported internationally by manufacturers and pharmacists alike, Aegate is a European company with offices throughout Europe. Our mission is to protect patients from falsified, recalled or expired medicines.
We operate a highly secure real‐time system to verify the authenticity of medicines. This operates seamlessly from manufacturer to pharmacy, and fully meets the requirements of European legislation for falsified medicines. The Aegate network also supports messaging services that provide additional information for the pharmacist at the point of dispense, such as regulatory or drug safety advice and patient education or adherence information.
For more information on Aegate, please visit http://www.aegate.com
Media contact information:
Head of Marketing & Communications